Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with S-1, nab-paclitaxel, and/or apatinib for conversion therapy in advanced unresectable gastric cancer
ChiCTR2100041825Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, tegafur + gimeracil + oteracil, nab-paclitaxel and Rivoceranib in gastric cancer (GC), sponsored by Xijing Hospital. Primary endpoint: R0 conversion rate. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumabtegafur + gimeracil + oteracilnab-paclitaxelRivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100041825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041825.